SGO: Change in Antigen Predicts Ovarian Cancer Outcomes - in Meeting Coverage early stage ovarian cancer

"The Gynecologic Oncology Group (GOG) 157 trial provided an opportunity to examine the change in CA-125 and its relationship to outcomes in women with early-stage ovarian cancer. The trial involved 427 women with stage I-II epithelial ovarian cancer. They were randomized to receive three or six cycles of chemotherapy with carboplatin and paclitaxel.
All patients had detailed surgical staging before randomization. Chan said detailed information about CA-125 levels was available for 350 participants in the trial."

"There is a lack of data in early-stage ovarian cancer on the pattern of CA-125," said Chan. "Previous studies generally had no comprehensive staging and no central pathology review."
"An elevated level that declined to normal after the first cycle of chemotherapy was associated with recurrence-free and overall survival of 87% and 88%, respectively.
Patients with an elevated CA-125 before and after the first cycle of chemotherapy had recurrence-free survival of 68% and overall survival of 77%."